Who is Celsee?
Celsee, Inc., is harnessing the gentle power of gravity to break down barriers in single-cell analysis.
Scaling easily to millions of cells, Celsee’s Genesis system offers an efficient approach for accurately analyzing rare cells. Its unparalleled capture and viability rates deliver results users can count on. This has immediate use in single-cell cytometry, proteogenomics, transcriptomics, and rare-cell enumeration.
Bulk cell analysis can’t see important variations among cells. At Celsee, we believe that more and more areas of life sciences will focus on single cells in the coming years as demand rises for precise and comprehensive information about heterogeneous samples.
Whether studying hundreds or millions of cells, Celsee’s platform provides a practical, scalable, and efficient approach to accurately analyze rare cells — all without the pitfalls common to other cell analysis technologies, such as causing damage or missing important cells.
Our Team
John Stark, Chief Executive Officer
After holding a variety of executive-level positions in the life sciences industry, John joined Celsee in 2017 to expand the company’s strategy, operations, and commercial efforts. His previous leadership roles include Senior Vice President of Global Applied Commercial Operations at Fluidigm and Vice President of Clinical Sequencing Commercial Operations at Thermo Fisher Scientific (formerly Life Technologies). He was also involved in assembling and scaling commercial organizations, including Pacific Biosciences and Affymetrix, leading to explosive growth in the genomics and sequencing markets. John received a BS from Western Michigan University in Biomedical Sciences and an MS from Arizona State University in Biomedical Engineering.
Kalyan Handique, Chief Technology Officer
Kalyan is an experienced serial entrepreneur with deep domain knowledge in microfluidics and medical devices. Prior to founding Celsee, he was a founder of HandyLab, a molecular diagnostic startup based in Ann Arbor, Michigan, that was sold to Becton Dickinson in late 2009 for $275 million. He serves as an advisor and board member to many startup companies in the Michigan Biotech Region. Kalyan completed his PhD in Chemical Engineering at the University of Michigan and earned his bachelor’s degree in chemical engineering from the Indian Institute of Technology in Bombay.
Patrick Cooke, Chief Operating Officer
Pat has 20 years of experience in the life sciences industry. He is the Chief Operating Officer and runs manufacturing, logistics, service, support, and internal applications. Prior to joining Celsee, he either served or built service and support organizations (in both regulated and non-regulated markets) at Fluidigm, Ion Torrent/Life Technologies/Thermo Fisher, Pacific Biosciences, and Affymetrix. Pat holds a PhD in microbiology from the University of North Texas, Denton. He did his postdoc at Oklahoma Medical Research Foundation in Oklahoma City, where he worked with his mentor and others to help build the first microarray and bioinformatics core facility in the state.
David Coe, Vice President, Head of Marketing
David leads the marketing efforts at Celsee, including commercial strategy and direction. He was also an integral leader in the sales department when he first joined the company. Previously, David served as Senior Commercial Development Manager at Illumina, where he focused on translational oncology and single-cell applications. He also worked in sales at Fluidigm and BioTek Instruments. David earned his BS from Ashland University, his PhD in biochemistry from the University of Toledo, and conducted his postdoctoral fellowship at the Cleveland Clinic studying developmental biology.
Lisa Sherman, Vice President, Finance
Lisa is responsible for Celsee’s financial functions, including finance and accounting. She began her career in public accounting after earning her bachelor’s from Walsh College and becoming licensed as a CPA. Later, she migrated to private industry to serve as controller for Huron Valley Financial, Inc., and for PrizeLogic. Her work there involved financial planning and analysis, compliance, and program management.
Todd Pollard, Senior Vice President, Corporate Development
Todd is an experienced commercial leader with a proven track record of building organizations. He has spent the last 20 years driving genetic analysis product portfolios within the life science, pharmaceutical, and diagnostic industries. Todd has held senior and executive management positions with companies such as ArcherDx, Affymetrix, Life Technologies, and Thermo Fisher Scientific. Todd has been responsible for several key partnership initiatives resulting in the FDA approval of multiple drug compounds and diagnostic tests. He received his BS degree in biology with honors from Oakland University in Rochester, Mich.
Swati Ranade, Senior Director, Applications Development
Swati provides leadership to the R&D organization for creating novel applications in the single-cell analysis market. During her career, she has made several scientific and technical contributions that have resulted in more than 30 high-impact, peer-reviewed publications and led to the development of revenue-generating products. In her previous role at Pacific Biosciences, she led development of the SMRT Sequencing-based HLA genotyping application for pre-transplant donor-recipient matching. Swati has also worked at Agencourt Personal Genomics, Applied Biosystems, and Life Technologies. She received her PhD in biochemistry from The University of Pune in India and performed her postdoctoral work at Harvard Medical School.
Our Board
John Stark
After holding a variety of executive-level positions in the life sciences industry, John joined Celsee in 2017 to expand the company’s strategy, operations, and commercial efforts. His previous leadership roles include Senior Vice President of Global Applied Commercial Operations at Fluidigm and Vice President of Clinical Sequencing Commercial Operations at Thermo Fisher Scientific (formerly Life Technologies). He was also involved in assembling and scaling commercial organizations, including Pacific Biosciences and Affymetrix, leading to explosive growth in the genomics and sequencing markets. John received a BS from Western Michigan University in Biomedical Sciences and an MS from Arizona State University in Biomedical Engineering.
Kalyan Handique
Kalyan is an experienced serial entrepreneur with deep domain knowledge in microfluidics and medical devices. Prior to founding Celsee, he was a founder of HandyLab, a molecular diagnostic startup based in Ann Arbor, Michigan, that was sold to Becton Dickinson in late 2009 for $275 million. He serves as an advisor and board member to many startup companies in the Michigan Biotech Region. Kalyan completed his PhD in Chemical Engineering at the University of Michigan and earned his bachelor’s degree in chemical engineering from the Indian Institute of Technology in Bombay.
Walter Young
Walt has 50 years’ experience in leading organizations. For the first 36 years, he held senior positions at four public companies: BF Goodrich, The Budd Company, The Henley Group and Champion Enterprises. While at these four companies he completed 23 different turnarounds and more than 75 mergers and acquisitions. Since 2003, Walt has focused on entrepreneurial startups, including as a lead investor and Director for Accuri Cytometers (acquired by Becton, Dickinson for $205 million in 2011). He has led and assisted 80+ entities to raise more than $100 million in capital. Walt is an Advisor for the Michigan Accelerator Fund, focused on life science startups in Michigan. Walt received a BA in History and Economics from Muskingum University, his MBA in Marketing and Management from Penn State University, and an honorary doctorate in Public Service from Muskingum University.
Gregg Fergus
Gregg Fergus is currently the Chief Executive Officer and Chief Commercial Officer of 4Catalyzer, a Guilford, Connecticut-based startup accelerator dedicated to democratizing healthcare and maximizing societal impact. 4Catalyzer provides funding, support and mentoring, and has raised more than $600 million for four of its healthcare startup companies, including $250 million for Butterfly Network. Prior to joining 4Catalyzer, Gregg was the President and Chief Operating Officer of Ion Torrent, which pioneered an entirely new approach to DNA sequencing. He negotiated the sale of Ion Torrent to Life Technologies for $725 million. Gregg’s other previous executive roles include Executive in Residence at RW Baird/Baird Venture Partners, where he provided investment thesis, deal flow, and industry contacts for the life science tools market; Chief Commercial Officer of Cellular Dynamics International; and Senior Vice President of Sales and Global Operations at Affymetrix, Inc. Gregg also sits on the Board of LÜM (Live Undiscovered Music).
Timothy Triche
Tim is the emeritus Chair of Pathology and Founding Director of the Center for Personalized Medicine at Children’s Hospital Los Angeles, University of Southern California. He has focused his career on cancer since 1974 when he joined the National Cancer Institute at NIH, where he developed specialized cancer diagnostics. Over his career he has received more than $50 million in grants, published 250-plus peer-reviewed manuscripts, and founded or co-founded six biotech companies, including the first to perform cancer predisposition testing in 1993. He currently sits on the boards of four companies and advises investors and biotech companies on potential investment opportunities. He is a full-time faculty member at the USC Norris Cancer Center, engaged in cancer research and diagnosis. Most recently, he launched OncoKids, a childhood cancer gene panel to guide diagnosis and treatment of cancer in children, adolescents, and young adults.
Richard Sharp
Bio coming soon.
Roger S. Newton
Ph.D., FAHA, FACN is the Founder, Board Director, and former President/CEO, Executive Chairman, and Chief Scientific Officer at Esperion Therapeutics. He is a Fellow of the American Heart Association and the American College of Nutrition, where he also serves as its President. Dr. Newton is also a Board Director on a number of life science companies including Celsee, Juventas Therapeutics, and FirstSense Medical Products. He serves on several National Advisory Boards at the University of Michigan including the Life Science Institute, the Frankel Cardiovascular Center, and the Alfred Taubman Medical Research Institute. Dr. Newton is also an Executive-in- Residence at the Center for Positive Organizations at the University of Michigan Ross School of Business. Lastly, he has served on the Technical Advisory Board of Arboretum Ventures in Ann Arbor, MI since its founding in 2002.
Careers
Are you looking to push past traditional boundaries with an energetic life sciences startup aiming to change how scientists investigate cells and the precious information they contain? Celsee is looking for some dynamic new team members to scale the company and their potential.
Locations
Celsee is conveniently located south of downtown Ann Arbor, Michigan. Our headquarters have ample parking, as well as a on-site gym and cafeteria. But we also recognize ourselves as a global growing company, with team members located all over the U.S. as well as in Europe.
The Celsee Experience
The perks include flexible work schedules and the ability to work remotely.
Additional benefits include:
- Generous paid time off
- Comprehensive health, prescription, dental and vision insurance
- 401k
- Flexible Spending Account (FSA) and Health Savings Account (HSA)
- Short and Long Term Disability insurance
